Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats

Nephrology Dialysis Transplantation

Volumn 18, Issue 10, 2003, Pages 2005-2013

  Wenzel, Ulrich O ^a   Wolf, Gunter ^a   Jacob, Ivonne ^a   Schwegler, Christian ^a   Qasqas, Arish ^a   Amann, Kerstin ^b   Helmchen, Udo ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

ACE inhibitor; Enalapril; Glomerulosclerosis; Omapatrilat; Renovascular hypertension; Vasopeptidase inhibition

Indexed keywords

CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; NEUTRAL PROTEINASE; OMAPATRILAT; TRANSFORMING GROWTH FACTOR BETA; UREA; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD VESSEL INJURY; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART INJURY; HEART PROTECTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZATION; RAT; RENOVASCULAR HYPERTENSION; UREA BLOOD LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENALAPRIL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERTENSION, RENAL; IMMUNOHISTOCHEMISTRY; MALE; ORGAN SIZE; PROBABILITY; PROTEASE INHIBITORS; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, INBRED STRAINS; REFERENCE VALUES; RENAL CIRCULATION; SURVIVAL RATE; THIAZEPINES;

EID: 0141730382     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg271     Document Type: Article

References (22)

1. Wenzel UO. Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001; 135: 200-211
2. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 35: 1525-1532
3. Jackson B, Franze C, Sumithran E, Johnston I. Pharmacologic nephrectomy with chronic angiotensin converting enzyme inhibitor treatment in renovascular hypertension in the rat. J Lab Clin Med 1990; 115: 21-27
4. Wenzel UO, Helmchen U, Troschau G et al. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992; 20: 233-241
5. Hannken T, Schroeder R, Stahl RA, Wolf G. Atrial natriuretic peptide attenuates ANG II-induced hypertrophy of renal tubular cells. Am J Physiol 2001; 281: F81-90
6. Shaw SG, Weidmann P, Hodler J et al. ANP protects against acute ischemic renal failure in the rat. J Clin Invest 1987; 80: 1232-1237
7. Trippodo NC, Robl JA, Asaad MM et al. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 1: 363-372
8. Taal MW, Nenov VD, Wong W et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 1998; 12: 2051-2059
9. Cohen DS, Mathis JE, Dotson RA et al. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998; 32: 87-95
10. Cao Z, Burrell LM, Tikkanen I et al. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001; 60: 715-721
11. Quaschning T, D'Uscio LV, Shaw S, Lüscher TF. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 2001; 37: 1108-1113
12. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000; 35: 1221-1225
13. Wenzel UO, Wolf G, Jacob I et al. Chronic anti-Thy-1 nephritis is aggravated in the nonclipped but not in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2002; 61: 2119-2131
14. Furuyama M. Histometrical investigations of arteries in reference to hypertension. Tohuku J Exp Med 1962; 76: 388-414
15. Mai M, Geiger H, Hilgers KF et al. Early interstitial changes in hypertension-induced renal injury. Hypertension 1993; 22: 754-765
16. Pu Q, Schiffrin EL. Effect of ACE/NEP inhibition on cardiac and vascular collagen in stroke-prone spontaneously hypertensive rats. Am J Hypertens 2001; 14: 1067-1072
17. Quaschning T, D'Uscio LV, Shaw S et al. Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol 2001; 12: 2280-2287
18. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985; 76: 612-619
19. Kakinuma Y, Kawamura T, Bills T et al. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46-55
20. Peters H, Border WA, Noble NA. Targeting TGF-β overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54: 1570-1580
21. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2002; 20: 899-907
22. Pettinger WA, Mitchell HC, Lee HC, Redman HC. Pseudo renal artery stenosis (PRAS) syndrome. Am J Hypertens 1989; 2: 349-351